| 16th Oct 2025 7:00 am |
RNS |
Appointments: Interim CEO and senior board advisor |
| 8th Oct 2025 7:00 am |
RNS |
Strategy Update |
| 29th Sep 2025 7:00 am |
RNS-R |
Presentation of Data on Glioblastoma |
| 12th Sep 2025 7:00 am |
RNS |
Board Changes |
| 9th Sep 2025 7:01 am |
RNS |
Interim Results |
| 9th Sep 2025 7:00 am |
RNS |
Change of Adviser |
| 5th Sep 2025 2:58 pm |
RNS |
Notice of Results |
| 20th Aug 2025 7:00 am |
RNS |
ANGLE announces collaboration with Myriad Genetics |
| 8th Jul 2025 7:00 am |
RNS-R |
PARSORTIX ENABLES STUDY OF CANCER PROGRESSION |
| 30th Jun 2025 5:50 pm |
RNS |
Result of 2025 Annual General Meeting |
| 17th Jun 2025 7:00 am |
RNS-R |
EACR 2025: Innovation in AR expression profiling |
| 17th Jun 2025 7:00 am |
RNS-R |
EACR 2025: Data demonstrating DNA dual analysis |
| 10th Jun 2025 7:00 am |
RNS-R |
Novel discoveries into the biology of cancer |
| 9th Jun 2025 7:00 am |
RNS |
POSTING OF ANNUAL REPORT AND NOTICE OF AGM |
| 6th Jun 2025 7:00 am |
RNS |
Board Changes |
| 28th May 2025 7:00 am |
RNS |
Preliminary Results |
| 23rd May 2025 7:00 am |
RNS |
Notice of Results |
| 28th Apr 2025 7:00 am |
RNS-R |
RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME |
| 21st Mar 2025 7:00 am |
RNS |
Issue of LTIP Options and Share Options |
| 21st Mar 2025 7:00 am |
RNS |
Results of Eisai Phase 2 pilot study |
| 6th Feb 2025 7:00 am |
RNS-R |
Novel findings using Parsortix |
| 29th Jan 2025 7:00 am |
RNS |
Analysis of CTC-DNA and ctDNA using Illumina assay |
| 24th Jan 2025 10:05 am |
RNS-R |
Parsortix used in research paper from ETH Zurich |
| 23rd Jan 2025 7:00 am |
RNS |
Trading Update |
| 26th Sep 2024 7:00 am |
RNS |
Half-year Report |
| 23rd Sep 2024 7:00 am |
RNS |
Exclusive agreement for DNA NGS panel |
| 17th Sep 2024 7:00 am |
RNS |
Notice of Interim Results and Webcast |
| 18th Jul 2024 10:08 am |
RNS |
Standard form for notification of major holdings |
| 12th Jul 2024 3:38 pm |
RNS |
Standard form for notification of major holdings |
| 11th Jul 2024 3:07 pm |
RNS |
Result of 2024 Annual General Meeting |
| 21st Jun 2024 7:00 am |
RNS |
Result of open offer |
| 18th Jun 2024 2:41 pm |
RNS |
Posting of 2023 Annual Report & Notice of the AGM |
| 11th Jun 2024 7:00 am |
RNS |
Parsortix and assays being showcased at EACR 2024 |
| 6th Jun 2024 4:37 pm |
RNS |
Publication of Circular |
| 5th Jun 2024 4:04 pm |
RNS |
Results of placing and subscription |
| 5th Jun 2024 7:00 am |
RNS |
Proposed Placing, Subscription and Open Offer |
| 5th Jun 2024 7:00 am |
RNS |
Preliminary Results |
| 16th May 2024 7:00 am |
RNS |
Study of ovarian cancer CTCs using Parsortix |
| 3rd May 2024 7:00 am |
RNS |
New commercial agreement with large pharma |
| 24th Apr 2024 7:00 am |
RNS |
New commercial agreement with AstraZeneca |
